Highlights of This Issue 2009

REVIEW

2011 BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics
Ryan S. Soderquist and Alan Eastman

SMALL MOLECULE THERAPEUTICS

2018 ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme
Allison E. Cherry, Brian R. Haas, Alipi V. Naydenov, Susan Fung, Cong Xu, Katie Swinney, Michael Wagenbach, Jennifer Freeling, David A. Canton, Jonathan Coy, Eric A. Horne, Barry Rickman, Juan Jesus Vicente, John D. Scott, Rodney J.Y. Ho, Denny Liggitt, Linda Wordeman, and Nephil Stella

2030 BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

2042 CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy
Holly E. Barker, Radhika Patel, Martin McLaughlin, Ulrike Schick, Shane Zaidi, Christopher M. Nutting, Katie L. Newbold, Shreerang Bhide, and Kevin J. Harrington

2055 Acridine Derivatives as Inhibitors of the IRE1α–XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma
Dadi Jiang, Arvin B. Tam, Muthuraman Alagappan, Michael P. Hay, Aparna Gupta, Margaret M. Kozak, David E. Solow-Cordeno, Pek Y. Lum, Nicholas C. Denko, Amato F. Giaccia, Quynh-Thu Le, Maho Niwa, and Albert C. Koong

2066 A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells
Seijiro Toriyama, Mano Horinaka, Shusuke Yasuda, Tomoyuki Taniguchi, Yuichi Aono, Toshiya Takamura, Yukako Morioka, Tsumeharu Miki, Osamu Ukimura, and Toshiyuki Sakai

2076 αvβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-(RGDFK)4
Zhao-Hui Jin, Takako Furukawa, Melissa Degardin, Aya Sugyo, Atsushi B. Tsujii, Tomotero Yamasaki, Kazunori Kawamura, Yasuhisa Fujibayashi, Ming-Rong Zhang, Didier Boturyn, Pascal Dumy, and Tsuneo Saga

2086 Vitamin D Enhances the Efficacy of Irinotecan through miR-627–Mediated Inhibition of Intratumoral Drug Metabolism
Meiyan Sun, Qunshu Zhang, Xiaooyu Yang, Steven Y. Qian, and Bin Guo

2096 Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer
Wells S. Brown, Li Tan, Andrew Smith, Nathanael S. Gray, and Michael K. Wendt

2107 Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer
Long Chen, Jie Li, Elia Fazah, Sukumar Sarkar, Nilah Ahmad, Sanjay Gupta, James Larner, and Xiaoqi Liu

2119 Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth

LARGE MOLECULE THERAPEUTICS

2130 A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells
Martina Schmittnaegel, Eike Hoffmann, Sabine Imhof-Jung, Cornelie Fischer, Georg Drabner, Guy Georges, Christian Klein, and Hendrik Knoetgen

2143 Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
Shanthi Ganesh, Martin L. Koser, Wendy A. Cyr, Girish R. Chopda, Junyan Tao, Xue Shu, Bo Ying, Dongyu Chen, Purva Pandya, Edmond Chippuuro, Zakir Siddiqui, Kevin Craig, Chengjun Lai, Henryk Dudek, Sadatshan P. Monga, Weimin Wang, Bob D. Brown, and Marc T. Abrams
2155 MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Gabriela Hernandez-Hoyos, Toddy Sewell, Robert Bader, Jeannette Bannink, Ruth A. Chenault, Mollie Daugherty, Maria Dasovich, Hang Fang, Rebecca Gottschalk, John Kumer, Robert E. Miller, Padma Ravikumar, Jennifer Wiens, Paul A. Algate, David Bienvenue, Catherine J. McMahen, Sateesh K. Natarajan, Jane A. Gross, and John W. Blankenship

2166 Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models
Marc H.A. Jansen, Tonny Lagerweij, A. Charlotte P. Sewing, Danielle J. Vugts, Dannis G. van Vuurden, Carla F.M. Molthoff, Viola Caretti, Susanna J.E. Veringa, Naomi Petersen, Angel M. Carcaboso, David P. Noske, W. Peter Vandertop, Pieter Wesseling, Guus A.M.S. van Dongen, Gerjan J.L. van de Water, and Esther Hulleman

2175 Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab

CANCER BIOLOGY AND SIGNAL TRANSDUCTION
2187 Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
Soon Young Park, Yuji Piao, Kang Jin Jeong, Jianwen Dong, and John F. de Groot

2198 Bruton’s Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells
Xianhui Wang, Jason Wong, Christopher J. Sevinsky, Leila Kokabee, Faiza Khan, Yan Sun, and Douglas S. Conklin

2209 MiR-548an, Transcriptionally Downregulated by HIF1α/HDAC1, Suppresses Tumorigenesis of Pancreatic Cancer by Targeting Vimentin Expression
Shuai Zhu, Chi He, Shijiang Deng, Xiang Li, Shipeng Cui, Zhu Zeng, Mingliang Liu, Shufeng Zhao, Jingyun Chen, Yan Jin, Hengyu Chen, Shichang Deng, Yang Liu, Chunyou Wang, and Gang Zhao

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS
2220 Alternative Expression and Localization of Profilin 1/VASPpS157 and Cofilin 1/VASPpS239 Regulates Metastatic Growth and Is Modified by DHA Supplementation
Mehboob Ali, Kathryn Heyob, Naduparambil K. Jacob, and Lynette K. Rogers

2232 Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy
Le Li, Hua Chen, Yue Gao, Yong-Wei Wang, Guang-Quan Zhang, Shang-Ha Pan, Liang Ji, Rui Kong, Gang Wang, Yue-Hui Jia, Xue-Wei Bai, and Bei Sun

2244 A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer
Erin M. Bertino, Elizabeth L. McMichael, Xiaokui Mo, Prashant Trikha, Melanie Davis, Bonnie Paul, Michael Grever, William E. Carson, and Gregory A. Otterson

MODELS AND TECHNOLOGIES
2259 Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
Ilkka Liikanen, Siri Taltinen, Kilian Guse, Colleen Briner, Tomomi Kaneko, Sun-Young Rha, Oleg Gladkov, Susan G. Uha, Dina Sakaeva, Michael J. Pishvaian, Ruey-Kuen Hsieh, Wei-Ping Lee, and Heinz-Josef Lenz
ABOUT THE COVER

Recombinant fusion proteins of monoclonal antibodies and major histocompatibility class I complexes are potential therapeutics to increase antigenicity and facilitate elimination of tumor cells by CD8 effector T cells. This work explores novel formats to optimize potency, safety, and technical properties. For details, see the article by Schmittnaergel and colleagues beginning on page 2130.